BsAbs, an emergent immunotherapy class impaired by inefficient discovery processes that restrict widespread clinical use. Creative Biolabs deploys a state‐of‐the-art, high‐throughput screening platform incorporating phage display, yeast display, and rapid expression methodologies to robustly identify parent antibodies. Our innovative approach dramatically accelerates the immunotherapeutic pipeline, enabling the rapid generation of superior, cost‐effective BsAbs. By streamlining discovery, we aim to expand the clinical availability of these transformative agents, thereby enhancing therapeutic options across diverse disease indications and advancing the frontiers of immunotherapy remarkably.
Learn More
